Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06721013 · ClinicalTrials.gov registry record · Phase 1
A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
A Phase 1 study of Immune Thrombocytopenia (ITP), sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 58
- Enrollment target
- 20
- Study locations
NCT06721013 is a Phase 1 study of Immune Thrombocytopenia (ITP) that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 58 participants. The trial reports 20 study locations across 9 states.
The verdict
NCT06721013, a Phase 1 study of Immune Thrombocytopenia (ITP), is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 58 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo. The study drug will be administered orally in participants with Primary Immune Thrombocytopenia (ITP). Blood tests will be performed to check how much pirtobrutinib gets into the bloodstream and how long it takes the body to eliminate it. The study will last up to approximately 16 weeks for phase 1 dose-escalation and 28 weeks for phase 2 dose-optimization, excluding screening.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Pirtobrutinib
Study Locations (20)
Other
- Nanfang Hospital of Southern Medical University - Guangzhou
- Qilu Hospital of Shandong University - Jinan
- Hematology Hospital of the Chinese Academy of Medical Sciences - Tianjin
- Union Hospital Tongji Medical College Huazhong University of Science and Technology - Wuhan
- OUH - Odense C
- Hôpital Henri Mondor - Créteil
- CHU Dijon - Hopital du Bocage - Dijon
- CHU Bordeaux - Hôpital Haut-Lévêque - Pessac
- Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi IRCCS - Bologna
Texas
- Texas Oncology - Central South - Austin
- MD Anderson Cancer Center - Houston
- Texas Oncology Gulf Coast - The Woodlands
California
- USC Norris Comprehensive Cancer Center - Los Angeles
- Stanford University - Stanford
District of Columbia
- MedStar Georgetown University Hospital - Washington D.C.
Florida
- University of Miami Hospital and Clinics Sylvester Comprehensive Cancer Center - Miami
Illinois
- Bleeding and Clotting Disorders Institute - Peoria
Louisiana
- Ochsner Clinical Foundation - New Orleans
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2025-07-30 |
| Est. Completion | 2027-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06721013
The ClinicalTrials.gov registry entry for NCT06721013 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Immune Thrombocytopenia (ITP) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06721013 reports 20 study locations spanning 9 distinct geographic areas - top geographies include Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06721013 about?
NCT06721013 is a clinical study titled "A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia". The purpose of the phase 1 part of this study is to evaluate how well pirtobrutinib is tolerated and what side effects may occur. The phase 2 part of the study will further investigate efficacy and safety of multiple pirtobrutinib dosages versus placebo. The study drug will be administered orally i...
What is the current status of trial NCT06721013?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 58 participants. The study started on 2025-07-30. Estimated completion is 2027-02.
What conditions does trial NCT06721013 study?
This clinical trial studies the following conditions: Immune Thrombocytopenia (ITP).
What interventions are being tested in trial NCT06721013?
The interventions under investigation include: Placebo (DRUG), Pirtobrutinib (DRUG).
Who is sponsoring clinical trial NCT06721013?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06721013 being conducted?
This trial has 20 study locations across California, District of Columbia, Florida, Illinois, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Immune Thrombocytopenia (ITP)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.